Clancy J. Clark

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

Angela Alistar, Bonny Morris, Rodwige Desnoyer et al. · The Lancet Oncology · 2017 · 221 citations · Full text

Pancreatic Cancer, Modified Folfirinox, Medicine +9

Modified Frailty Index Predicts Morbidity and Mortality After Pancreaticoduodenectomy

Harveshp Mogal, Sarah A. Vermilion, Rebecca M. Dodson et al. · Annals of Surgical Oncology · 2017 · 155 citations

Pancreatic Cancer, Aging, Longevity +4

Phase II Randomized Trial of Negative-Pressure Wound Therapy to Decrease Surgical Site Infection in Patients Undergoing Laparotomy for Gastrointestinal, Pancreatic, and Peritoneal Surface Malignancies

Perry Shen, Aaron U. Blackham, Stacey Lewis et al. · Journal of the American College of Surgeons · 2017 · 114 citations · Full text

Modified frailty index predicts postoperative outcomes in older gastrointestinal cancer patients

Sarah A. Vermillion, Fang‐Chi Hsu, Robert Dorrell et al. · Journal of Surgical Oncology · 2017 · 113 citations

Clinical Outcomes for Neuroendocrine Tumors of the Duodenum and Ampulla of Vater:A Population-Based Study

Reese W. Randle, Shuja Ahmed, Naeem A. Newman et al. · Journal of Gastrointestinal Surgery · 2013 · 100 citations

Neuro-oncology, Endocrine Oncology, Urology +7